BDX announced a cash dividend of 0.95 with an ex-date of Dec. 7, 2023
|Bid||233.54 x 800|
|Ask||233.82 x 800|
|Day's Range||232.81 - 234.60|
|52 Week Range||228.62 - 287.32|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||45.89|
|Earnings Date||Jan 31, 2024 - Feb 05, 2024|
|Forward Dividend & Yield||3.80 (1.63%)|
|Ex-Dividend Date||Dec 07, 2023|
|1y Target Est||279.69|
Subscribe to Yahoo Finance Plus to view Fair Value for BDX
In this article, we will discuss top 25 dividend aristocrats among billionaires. You can skip our detailed analysis of dividend aristocrats and the performance of dividend growers in the past, and go directly to read Dividend Aristocrats List: Top 10 Among Billionaires. Investing in dividend stocks offers a distinct opportunity for investors seeking consistent income. […]
Becton Dickinson said on Thursday the U.S. Food and Drug Administration (FDA) cleared its finger-prick blood collection device that could provide a less-invasive option for some commonly ordered lab tests. The device, BD MiniDraw Collection System, can help collect blood samples from a patient's finger through a trained healthcare professional without the need to do it from a vein, the company said. The clearances include blood collection for commonly ordered lab tests such as for lipid panel and tests to diagnose and monitor a variety of chronic conditions from hypertension to high cholesterol, it said.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.